YD Life Science acquires approval of DR therapy for Phase 2a clinical trial in U.S.
YD Life Science(CEO Jin-Woo Lee) announced on the 21st that its diabetic retinopathy(DR) therapy ‘YD-312’ acquired final approval for a Phase 2a clinical trial from the U.S. Food and Drug Administration.
Diabetic retinopathy, a diabetes complication, is a dermatologic disease which affects eyes....
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.